Press Releases

11/12/2024

EMR Integration

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cl...

11/11/2024

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 pati...

11/08/2024

Tempus Announces Nine Abstracts Accepted For Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. "Presenting our latest research is a vit...

11/07/2024

Product Launch

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

IPS test validation study data will be unveiled at the 2024 SITC Annual Meeting Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians...

11/04/2024

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

CHICAGO, November 4, 2024 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leade...

10/31/2024

Tempus and Northwestern Medicine Announce Collaboration to Bring Practical Application of AI to Healthcare

Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago’s premier integrated academic health system, today announced a collaboration that aims to explore the application of artificial intelligence in clinical care and research. The collaboration, which is expected to span across several disease conditions...

10/28/2024

Tempus Announces Collaboration with JW Pharmaceutical to Apply Real-World Data and Biological Modeling to Enhance Early Research and Development

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with JW Pharmaceutical, one of the most established pharmaceutical companies in Korea, to leverage both real-world data (RWD) and biological modeling to support efficient hypothesis generation and rapid validation in early therapeutic research in oncology....

10/24/2024

Tempus to Report Third Quarter 2024 Financial Results on November 4

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the sa...

09/26/2024

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda’s...

09/13/2024

Oncology

Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024. "ESMO provides a great platform...

NEWS

Media Coverage

Additional Partnerships